Scleromyxedema: A scleroderma-like variant of mucinosis papulosa;Scleromyxedema - Twardzinopodobny variant mucinosis papulosa

Przeglad Dermatologiczny

Volumn 88, Issue 1, 2001, Pages 7-16

  Blaszczyk, M ^a   Jabonska S ^a  

^a Klinika Dermatologiczna Medical University of Warsaw   (Poland)

Author keywords

Gammopatia; Intravenous immunoglobulin G therapy (IVIG); Scleroderma like disorders; Scleromyxedema

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MALE; MUCINOSIS; MYXEDEMA; PROGNOSIS; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 0035050207     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states)
2. The mucinoses. A classification with histochemical studies on the nature of mucin
3. Fibromes miliaires folliculaires: Sclerodermie consecutive
4. Systematisierte Haut-Muskel-Amyloidose unter dem Bilde eines Skleroderma amyloidosum
5. Zur Pathogenese des Myxedema circumscriptum tuberosum
6. Skleromyxedem (eine eigenartige Erschein ungsform von Myxothesaurodermie)
7. Scleroderma-like disorders
8. Scleromyxedema is a scleroderma-like disorder and not a coexistence of scleroderma with papular mucinosis
9. Papular mucinosis (scleromyxedema) complicating diffuse systemic sclerosis: Clinical features and electron microscopic observations
10. Papular mucinosis associated with scleroderma
11. Mucin deposits in morphea and systemic scleroderma
12. Papular mucinosis associated with generalized morphoea
13. Mucinosis papulosa-scleromyxedema
14. Connective tissue in scleroderma, a biochemical study on the correlation of fractionated glycosominoglycans and collagen in human skin
15. Progressive systemic sclerosis (PSS, scleroderma) dermal fibroblasts synthesize increased amounts of glycosaminoglycans
16. Scleromyxedema associated with scleroderma renal disease and acute psychosis
17. Fatal scleromyxedema: Report of a case and review of the literature
18. Myeloma associated sc leromyxedema with extensive involvement of small bowel
19. Scleromyxedema associated with synovitis and myopathy
20. Scleromyxedema associated with arthritis and myopathy: A case report
21. Scleromyxedema with myopathy and hyperthyroidism
22. Scleromyxedema myopathy: Case report and review of the literature
23. Mucinose papuleuse avec myopathie
24. The association of potentially lethal neurological syndromes with scleromyxedema (papular mucinosis)
25. Fever, convulsions and coma in scleromyxedema: A "dermato-neuro syndrome"
26. Scleromyxedema with dermato-neuro syndrome
27. Spontaneous resolution of lichen myxeoedematosus
28. Spontaneous improvement of scleromyxedema
29. Further observations on lichen myxedematosus
30. The role of glycosphingolipids in neurological disorders: Mechanisms of immune action
31. Scleromyxedema
32. Scleromyxedema with systemic involvement mimics rheumatic diseases
33. Scleromyxedema a scleroderma-like disorder with systemic manifestations
34. Scleromyxedema myopathy: Histochemical and electromicroscopic observations
35. Immunologic markers of systemic scleroderma in children
36. Clinical relevance of immunologic findings in scleroderma
37. Lichen myxedematosus serum stimulates human skin fibroblast proliferation
38. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts
39. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin production by human fibroblasts
40. Scleromyxedema, a dramatic response to melphalan
41. Treatment of scleromyxedema with melphalan
42. Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema
43. High dose intravenous immunoglobulin therapy for rheumatic disease: Clinical relevance and personal experience
44. Immunoglobulins in autoimmunity: History and mechanisms of action
45. Mechanism of intravenous immune globulin therapy in antibody mediated autoimmune diseases
46. Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)